Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

347.60 -3.46 (-0.99%)
Streaming Delayed Price Updated: 12:15 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Where BeOne Medicines Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Expectations For BeOne Medicines's Future ↗
 
Via Benzinga
News headline image
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features ↗
  BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating... 
Via Benzinga
News headline image
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA. 
Via Investor's Business Daily
Topics Economy Government
News headline image
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions. 
Via Benzinga
News headline image
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Present at Upcoming Investor Conferences
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally ↗
Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
From BeOne Medicines Ltd.
Via Business Wire
News headline image
What's Going On With Summit Therapeutics Stock On Monday? ↗
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025. 
Via Benzinga
News headline image
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
From BeOne Medicines Ltd.
Via Business Wire
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients ↗
BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress. 
Via Benzinga
News headline image
Affirm Posts Better-Than-Expected Earnings, Joins Ambarella, IREN, Petco Health and Wellness And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
From BeOne Medicines Ltd.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.